Background: This review provides a comprehensive summary of the production of 177 Lu to
meet expected future research and clinical demands. Availability of options represents the …

Interest in the use of radionuclides for treatment of various diseases has a long history and
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …

Radionuclide therapy (RNT) based on the concept of delivering cytotoxic levels of radiation
to disease sites is one of the rapidly growing fields of nuclear medicine. Unlike conventional …

Bone metastasis develops in multiple malignancies with a wide range of incidence. The
presence of multiple bone metastases, leading to a multitude of complications and poorer …

Purpose The purpose of this study was to evaluate the efficacy and safety of 177 Lu-EDTMP
for pain palliation in patients with bone metastases from castration-resistant prostate and …

Lutetium-177 has been widely discussed as a radioisotope of choice for targeted
radionuclide therapy. The simultaneous emission of imageable gamma photons [208 keV …

Purpose 177 Lu-labeled ethylenediamine-N, N, N′, N′-tetrakis methylene phosphonic
acid (177 Lu-EDTMP), was used to palliate metastatic bone pain as a new bone-seeking …

Purpose We designed and synthesized a novel theranostic bisphosphonate
radiopharmaceutical (68 Ga-or 177 Lu-labeled DOTA-ibandronic acid [68 Ga/177 Lu-DOTA …

Several radiolanthanides find their application in nuclear medicine because of their
favorable decay properties, the most important ones being 143 Pr, 149 Pm, 153 Sm, 165 Dy …

Therapeutic phosphonate-based radiopharmaceuticals radiolabeled with beta, alpha and
conversion electron emitting radioisotopes have been investigated for the targeted treatment …